Table 3.

State of progress of clinical trials with anti-amyloid drugs.

Treatment	Preclinical experimental	Administration	Phase I	Phase II	Phase III	Marketing authorization
Tafamidis*	–	Oral		2007	−>2009	EMA : November 2011 ANSM: September 2011 FDA: No
Diflunisal$	–	Oral			−>2010
DOXY-TUDCA‡	+	Oral		Current
ASOs§	+	SCI	Current		2013
SiRNA¶	+	IVI	2011–2012	2012	2013?
Anti-SAP Mab#	+	IVI	2013?

^* Coelho et al. [2012]; ^$ Berk et al. [2011]; ^‡ Cardoso et al. [2010], Obici et al. [2012]; ^§ Ackermann et al. [2012], Benson et al. [2006]; ^¶ Coelho et al. [2011]; ^# Bodin et al. [2010].

ANSM, Agence nationale de sécurité du médicmanet et des produits de santé; ASO, antisense oligonucleotide; DOXY-TUDCA, doxycycline taurodesoxycholic acid; EMA, European Medicines Agency; FDA, US Food and Drug Administration; IVI, intravenous infusion; SCI, subcutaneous injection.